AN 215

Drug Profile

AN 215

Alternative Names: AN-215

Latest Information Update: 06 Oct 2008

Price : $50

At a glance

  • Originator AEterna Zentaris Inc; Tulane University School of Medicine; Zentaris
  • Developer AEterna Zentaris GmbH; Tulane University School of Medicine
  • Class Antineoplastics
  • Mechanism of Action DNA intercalators; Gastrin-releasing peptide inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 06 Oct 2008 Discontinued - Preclinical for Solid tumours in USA (IV)
  • 01 Jun 2006 This compound is still in active development
  • 27 Oct 2005 A preclinical study has been added to the Cancer pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top